Related Experiment Videos
[New pharmacological treatment concepts for overactive bladder].
1Abteilung Pharmakologie und Pharmakotherapie, Universität, Amsterdam, Netherlands. m.c.michel@amc.uva.nl
Der Urologe. Ausg. A
|July 10, 2003
Summary
Muscarinic receptor antagonists treat overactive bladder but cause dry mouth. New extended-release formulations improve tolerability and maintain efficacy, offering better treatment options.
Area of Science:
- Pharmacology
- Urology
Background:
- Muscarinic receptor antagonists (e.g., oxybutynin, tolterodine) are first-line treatments for overactive bladder.
- These drugs exhibit moderate efficacy but are limited by anticholinergic side effects like dry mouth.
Purpose of the Study:
- To review current and emerging treatments for overactive bladder.
- To evaluate the potential of novel pharmaceutical formulations in improving drug tolerability and efficacy.
Main Methods:
- Review of existing literature on overactive bladder pharmacotherapy.
- Analysis of clinical study data for extended-release formulations of existing drugs.
Main Results:
- Extended-release formulations of oxybutynin and tolterodine show improved tolerability compared to standard formulations.
- Efficacy of extended-release formulations is comparable to standard formulations.
Conclusions:
- Optimizing existing drug formulations is a key strategy for improving overactive bladder treatment.
- Extended-release formulations offer a promising approach to enhance patient compliance and therapeutic outcomes.